Meeting
2021 Genitourinary Cancers Symposium
SGNTUC-019: Phase II basket study of tucatinib (TUC) and trastuzumab (Tras) in previously treated solid tumors with HER2 alterations: Urothelial cancer cohort (trial in progress).
Authors
Evan Y. Yu
Division of Oncology, Department of Medicine, University of Washington, Seattle, WA
Evan Y. Yu , Vicky Kang , Luke N. Walker , Matt D. Galsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04579380
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr TPS499)
DOI
10.1200/JCO.2021.39.6_suppl.TPS499
Abstract #
TPS499
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: Urothelial cancer cohort (SGNTUC-019).
First Author: Evan Y. Yu
Poster
2022 ASCO Genitourinary Cancers Symposium
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations—Urothelial cancer cohort (trial in progress).
First Author: Matt D. Galsky
Poster
2021 ASCO Annual Meeting
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress).
First Author: Tom Stinchcombe
Poster
2022 ASCO Annual Meeting
Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors.
First Author: Sadakatsu Ikeda